Gender-Affirming Hormone Therapy for Breast Cancer in Transgender and Gender-Diverse Individuals
Transgender and gender-diverse (TGD) individuals have a gender identity that does not align with the sex they were assigned at birth. In 2022, approximately 1.6% of US adults identified as TGD.1 Transgender and gender-diverse individuals may undergo multidisciplinary care to align their physical appearance with their gender identity, including estrogen and androgen-based gender-affirming hormone therapy (GAHT) and surgical interventions, which have been shown to improve their quality of life.2
